NHF’s Physical Therapist of the Year Award is named in honor of Donna Boone.
NHF's gala raised more than $370,000 to support programs and services for people with bleeding disorders.
Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy is free and avaliable for continung education credits.
The findings of this prevalence-based study could have significant future implications.
UniQure plans to exceed its original recruitment goal by "over-enrolling" an additional six trial participants by the end of September.
Marstacimab would represent an alternative approach to standard factor VII or factor IX replacement therapy.
Orphan Drug Designation is awarded by the U.S. FDA to therapies designed to treat rare diseases affecting fewer than 200,000 people in the United States.
The new blood-based screening tool represents an alternative to a standard clot-based FVIII test which cannot accurately determine inhibitor levels in patients receiving Hemlibra®.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car